Neuropace (NASDAQ: NPCE) net income
Neuropace reported a net loss of $21.5m for fiscal 2025; in fiscal 2024 it reported a net loss of $27.1m. Earnings per share were −$0.66.
Fiscal 2025 is the highest of the 6 fiscal years on record for Neuropace. It reported a loss in 6 of those 6 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | −$21.5m | — | −21.5% | −$0.66 |
| 2024 | −$27.1m | — | −34.0% | −$0.93 |
| 2023 | −$33.0m | — | −50.4% | −$1.27 |
| 2022 | −$47.1m | — | −103.4% | −$1.91 |
| 2021 | −$36.1m | — | −79.9% | −$2.17 |
| 2020 | −$24.3m | — | −59.0% | −$117.85 |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Neuropace net income compared with its sector
By net income for its latest fiscal year, Neuropace ranks 212th of the 501 US health care companies with a page on Celsmar. The sector median net margin is −6.2%; that of Neuropace, −21.5%.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 210th | GeneDx | −$21.0m | −4.9% |
| 211th | CareDx | −$21.4m | −5.6% |
| 212th | Neuropace | −$21.5m | −21.5% |
| 213th | Stereotaxis | −$21.6m | −66.8% |
| 214th | Inogen | −$22.7m | −6.5% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of Neuropace
- How much did Neuropace earn in fiscal 2025?
- Neuropace reported a net loss of $21.5m for fiscal 2025. In fiscal 2024 it reported a net loss of $27.1m.
- What are the earnings per share of Neuropace?
- They were −$0.66 in fiscal 2025, compared with −$0.93 in fiscal 2024.
- Where does Neuropace rank in its sector by net income?
- It ranks 212th of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Neuropace come from?
- From the annual report (Form 10-K) that Neuropace files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Neuropace files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020. More on Neuropace: the Neuropace page · annual accounts · revenue · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.